ABSORPTION, TISSUE DISTRIBUTION AND IN-VIVO STABILITY IN RATS OF A HYBRID ANTISENSE OLIGONUCLEOTIDE FOLLOWING ORAL-ADMINISTRATION

被引:113
作者
AGRAWAL, S
ZHANG, XS
LU, ZH
ZHAO, H
TAMBURIN, JM
YAN, YM
CAI, HY
DIASIO, RB
HABUS, I
JIANG, ZW
IYER, RP
YU, D
ZHANG, RW
机构
[1] UNIV ALABAMA,DEPT PHARMACOL & TOXICOL,BIRMINGHAM,AL 35294
[2] UNIV ALABAMA,DIV CLIN PHARMACOL,BIRMINGHAM,AL 35294
关键词
ANTISENSE OLIGONUCLEOTIDES; HIV; ORAL BIOAVAILABILITY;
D O I
10.1016/0006-2952(95)00160-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In vivo stability and oral bioavailability of an oligodeoxynucleotide phosphorothioate containing segments of 2'-O-methyloligoribonucleotide phosphorothioates at both the 3'- and 5'-ends (hybrid oligonucleotide) were studied. A 25-mer S-35-labeled hybrid oligonucleotide was administered to rats by gavage at a dose of 50 mg/kg body weight. HPLC analysis revealed that this hybrid oligonucleotide was stable in the gastrointestinal tract for up to 6 hr following oral administration. Radioactivity associated with the hybrid oligonucleotide was detectable in portal venous plasma, systemic plasma, various tissues, and urine. Intact hybrid oligonucleotide was detected, by HPLC analysis, in portal venous plasma, systemic plasma, and various tissues. The majority of the radioactivity in urine was associated with degradative products with lower molecular weights, but the intact form was also detected. In summary, the hybrid oligonucleotide was absorbed intact through the gastrointestinal tract, indicating the possibility of oral administration of oligonucleotides, a finding that may be important in the development of antisense oligonucleotides as therapeutic agents.
引用
收藏
页码:571 / 576
页数:6
相关论文
共 14 条
[1]   PHARMACOKINETICS, BIODISTRIBUTION, AND STABILITY OF OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATES IN MICE [J].
AGRAWAL, S ;
TEMSAMANI, J ;
TANG, JY .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (17) :7595-7599
[2]   PHARMACOKINETICS OF ANTISENSE OLIGONUCLEOTIDES [J].
AGRAWAL, S ;
TEMSAMANI, J ;
GALBRAITH, W ;
TANG, JY .
CLINICAL PHARMACOKINETICS, 1995, 28 (01) :7-16
[3]  
Cook P.D., 1993, ANTISENSE RES APPL, P149
[4]  
COSSUM PA, 1994, J PHARMACOL EXP THER, V269, P89
[5]  
COSSUM PA, 1993, J PHARMACOL EXP THER, V267, P1181
[6]   A PHARMACOKINETIC EVALUATION OF C-14-LABELED AFOVIRSEN SODIUM IN PATIENTS WITH GENITAL WARTS [J].
CROOKE, ST ;
GRILLONE, LR ;
TENDOLKAR, A ;
GARRETT, A ;
FRATKIN, MJ ;
LEEDS, J ;
BARR, WH .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (06) :641-646
[7]  
IVERSEN P, 1993, ANTISENSE RES APPLIC, P461
[8]   PHARMACOKINETICS OF AN ANTISENSE PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDE AGAINST REV FROM HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN THE ADULT MALE-RAT FOLLOWING SINGLE INJECTIONS AND CONTINUOUS-INFUSION [J].
IVERSEN, PL ;
MATA, J ;
TRACEWELL, WG ;
ZON, G .
ANTISENSE RESEARCH AND DEVELOPMENT, 1994, 4 (01) :43-52
[9]   STUDY OF ANTISENSE OLIGONUCLEOTIDE PHOSPHOROTHIOATES CONTAINING SEGMENTS OF OLIGODEOXYNUCLEOTIDES AND 2'-O-METHYLOLIGORIBONUCLEOTIDES [J].
METELEV, V ;
LISZIEWICZ, J ;
AGRAWAL, S .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1994, 4 (24) :2929-2934
[10]  
MONIA BP, 1993, J BIOL CHEM, V268, P14514